L'intérêt à découvert pour RadNet donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de RadNet. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

RadNet (NASDAQ:RDNT) Stock, Rapport sur les intérêts à découvert

RadNet

RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.

RadNet Inc

DaVita, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>) has witnessed strong momentum year to date, with its shares up 47.3% compared with the&nbsp;industry&#39;s&nbsp;growth of 14.8%. The S&amp;P 500 composite has risen 19.5% in the same period.
DaVita,&nbsp;carrying a Zacks Rank #2 (Buy) at present, is witnessing an upward trend in its stock price, prompted by the company&#39;s business model. The optimism, led by a solid second-quarter 2024 performance and the acquisition of dialysis centers, is expected to contribute further.
DaVita is a leading provider of dialysis services in the United States to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services, primarily in dialysis centers and contracted hospitals across the country. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/39/80935.jpg?v=255633029" />
Image Source: Zacks Investment Research
<h2>Catalysts Driving DaVita&#39;s Growth</h2>
The rally in the company&#39;s share price can be attributed to the strength of its dialysis and related lab services. The optimism led by a solid second-quarter 2024 performance and robust business potential are expected to contribute further.
DaVita is experiencing significant growth driven by its patient-centric care approach, leveraging its kidney care services platform to offer a wide range of treatment models and modalities. The increasing prevalence of value-based partnerships in kidney health enables nephrologists, physicians, and transplant programs to collaborate more effectively, enhancing the understanding of individual patient needs and facilitating improved care coordination and early interventions.
A key element of DaVita&#39;s growth strategy is the acquisition of dialysis centers and related businesses, as evident from the recent extension of its pilot phase for a supply and collaboration agreement with Nuwellis. Upon completion of this phase, which ends on Aug. 31, 2024, DaVita may extend the agreement for the ongoing provision of inpatient and outpatient ultrafiltration services for up to 10 years.
The company&#39;s global market share is also on the rise, with recent agreements to expand operations into Brazil, Colombia, Chile and Ecuador.
In the second quarter of 2024, DaVita reported results that exceeded expectations, showcasing a positive trend in both revenue streams and patient services. The sequential increase in daily United States dialysis treatments and the opening of new centers, along with acquisitions overseas, indicates a strong growth trajectory.
Furthermore, DaVita has raised its earnings projections for fiscal 2024, now forecasting adjusted EPS in the range of $9.25 to $10.05, up from the prior range of $9 to $9.80, which is likely to attract further interest from investors.
<h2>Risk Factor</h2>
DaVita faces a risk of reduced profitability if patients shift from commercial insurance to government programs, as government reimbursement rates are significantly lower. This shift could be triggered by rising unemployment, impacting DaVita&#39;s revenues and profit margins.
<h2>A Look at Estimates</h2>
The Zacks Consensus Estimate for DaVita&#39;s 2024 and 2025 bottom line projects an 18% and 14.4% year-over-year improvement, respectively, to earnings of $9.99 and $11.42 per share.
In the past 30 days, the Zacks Consensus Estimate for the company&#39;s 2024 earnings has remained constant at $9.99 per share.
Revenues for 2024 and 2025 are anticipated to rise 5.4% and 4%, respectively, to $12.8 billion and $13.3 billion on a year-over-year basis.
<div class="chart_embed">
<h3>DaVita Inc. Price</h3>
<img alt="DaVita Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/2b/1728478167.png" style="height:251px; width:544px" title="" />
DaVita Inc. price | DaVita Inc. Quote
</div>
<h2>Other Key Picks</h2>
Some other top-ranked stocks in the broader medical space are Rockwell Medical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rmti#NASDAQ">RMTI</a>), Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>)&nbsp;and RadNet (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdnt#NASDAQ">RDNT</a>). While Rockwell Medical carries a Zacks Rank #1 (Strong Buy), Quest Diagnostics&nbsp;and RadNet carry a Zacks Rank #2 each at present.
Rockwell Medical&nbsp;earnings surpassed estimates in each of the trailing four quarters, with the average being 87.9%.
RMTI&#39;s shares have gained 79.7% compared with the industry&#39;s 10.7% growth year to date.
Quest Diagnostics&nbsp;has an estimated long-term growth rate of 6.8%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average being 3.3%.
Quest Diagnostics&nbsp;has gained 7.9% compared with the industry&#39;s 14.9% growth year to date.
RadNet&#39;s&nbsp;earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 98.2%.
RDNT&#39;s shares have gained 93.7% year to date compared with the industry&#39;s&nbsp;14.8% growth.
<a href="https://www.zacks.com/stock/news/2348406/davita-stock-gains-47-3-year-to-date-what-s-behind-the-rally?cid=CS-BENZ-FT-analyst_blog|price_surge_/_plunge-2348406">To read this article on Zacks.com click here.</a>

Earnings

Earnings Beats

Large Cap

Mid Cap

News

Penny Stocks

Health Care

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

RDNT

RMTI

DaVita Stock Gains 47.3% Year to Date: What's Behind the Rally?

In the latest quarter, 7 analysts provided ratings for RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>), showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $70.29, along with a high estimate of $80.00 and a low estimate of $51.00. This upward trend is apparent, with the current average reflecting a 15.78% increase from the previous average price target of $60.71.
<img src="https://www.benzinga.com/files/images/story/2024/1727103646_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive RadNet. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$79.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$57.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$51.00</td>
<td>$48.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to RadNet. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of RadNet compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of RadNet's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of RadNet's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RDNT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on RadNet analyst ratings.</a>
<h2>Unveiling the Story Behind RadNet</h2>
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.
<h3>Understanding the Numbers: RadNet's Finances</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: RadNet's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 13.87%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: RadNet's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -0.65%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -0.34%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): RadNet's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.1%, the company may face hurdles in achieving optimal financial performance.
Debt Management: RadNet's debt-to-equity ratio surpasses industry norms, standing at 1.95. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 7 Analyst Insights On RadNet

Truist Securities analyst David Macdonald maintains RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) with a Buy and raises the price target from $70 to $80.

Price Target

Truist Securities Maintains Buy on RadNet, Raises Price Target to $80

Jefferies analyst Brian Tanquilut maintains RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) with a Buy and raises the price target from $75 to $80.

Jefferies Maintains Buy on RadNet, Raises Price Target to $80

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $66.4, along with a high estimate of $79.00 and a low estimate of $51.00. Marking an increase of 18.57%, the current average surpasses the previous average price target of $56.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1725627716_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive RadNet. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$79.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$57.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$51.00</td>
<td>$48.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to RadNet. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of RadNet compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into RadNet's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RDNT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on RadNet analyst ratings.</a>
<h2>About RadNet</h2>
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.
<h3>Understanding the Numbers: RadNet's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining RadNet's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 13.87% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: RadNet's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -0.65%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -0.34%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.1%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 1.95, RadNet faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Peeling Back The Layers: Exploring RadNet Through Analyst Insights

Barclays analyst Andrew Mok upgrades RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) from Equal-Weight to Overweight and raises the price target from $57 to $79.

Upgrades

Barclays Upgrades RadNet to Overweight, Raises Price Target to $79

Making a noteworthy insider sell on August 22, Michael Murdock, EVP at RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>), is reported in the latest SEC filing.
What Happened: After conducting a thorough analysis, Murdock sold 15,000 shares of RadNet. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000790526/000168316824005973//Archives/edgar/data/790526/000168316824005973/0001683168-24-005973-index.htm">U.S. Securities and Exchange Commission</a> on Thursday. The total transaction value is $941,701.
RadNet's shares are actively trading at $63.61, experiencing a down of 0.73% during Friday's morning session.
<h3>About RadNet</h3>
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.
<h3>Breaking Down RadNet's Financial Performance</h3>
Revenue Growth: RadNet's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 13.87%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company shows a low gross margin of 15.22%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, RadNet exhibits below-average bottom-line performance with a current EPS of -0.04.
</li>
</ul>
Debt Management: RadNet's debt-to-equity ratio stands notably higher than the industry average, reaching 1.95. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 355.94, RadNet's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 2.65 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): RadNet's EV/EBITDA ratio at 17.92 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Insider transactions serve as a piece of the puzzle in investment decisions, rather than the entire picture.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Breaking Down the Significance of Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000790526">Check Out The Full List Of RadNet's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

EVP Of RadNet Sold $941K In Stock

Across the recent three months, 5 analysts have shared their insights on RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for RadNet, presenting an average target of $63.2, a high estimate of $75.00, and a low estimate of $51.00. This current average reflects an increase of 13.67% from the previous average price target of $55.60. 
<img src="https://www.benzinga.com/files/images/story/2024/1723132847_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive RadNet. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$57.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$51.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$63.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to RadNet. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of RadNet compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for RadNet's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of RadNet's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RDNT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on RadNet analyst ratings.</a>
<h2>All You Need to Know About RadNet</h2>
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.
<h3>Financial Milestones: RadNet's Journey</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining RadNet's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.53% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: RadNet's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -0.64%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): RadNet's ROE excels beyond industry benchmarks, reaching -0.37%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): RadNet's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.1%, the company may face hurdles in achieving optimal financial performance.
Debt Management: RadNet's debt-to-equity ratio is below the industry average at 1.74, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For RadNet

WIIM

RadNet shares are trading higher after the company reported better-than-expected Q2 revenue results. Also, Barclays raised its price target on the stock from $51 to $57.

Barclays analyst Andrew Mok maintains RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) with a Equal-Weight and raises the price target from $51 to $57.

Barclays Maintains Equal-Weight on RadNet, Raises Price Target to $57

Guidance

RadNet Sees FY24 Revenue $1.685B-$1.735B Vs $1.763B Est.

RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.17 by 5.88 percent. The company reported quarterly sales of $459.714 million which beat the analyst consensus estimate of $438.502 million by 4.84 percent. This is a 13.87 percent increase over sales of $403.715 million the same period last year.

Earnings Misses

RadNet Q2 2024 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $459.714M Beat $438.502M Estimate

Truist Securities analyst David Macdonald maintains RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) with a Buy and raises the price target from $63 to $70.

Truist Securities Maintains Buy on RadNet, Raises Price Target to $70

4 analysts have shared their evaluations of RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for RadNet, presenting an average target of $62.25, a high estimate of $75.00, and a low estimate of $51.00. Surpassing the previous average price target of $53.50, the current average has increased by 16.36%.
<img src="https://www.benzinga.com/files/images/story/2024/1720710043_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of RadNet among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$51.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$63.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to RadNet. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of RadNet compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of RadNet's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into RadNet's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RDNT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on RadNet analyst ratings.</a>
<h2>All You Need to Know About RadNet</h2>
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.
<h3>Understanding the Numbers: RadNet's Finances</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: RadNet's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 10.53%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: RadNet's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -0.64%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): RadNet's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.37%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.1%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: RadNet's debt-to-equity ratio is below the industry average at 1.74, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For RadNet

Jefferies analyst Brian Tanquilut maintains RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) with a Buy and raises the price target from $61 to $75.

Jefferies Maintains Buy on RadNet, Raises Price Target to $75

Barclays analyst Andrew Mok maintains RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) with a Equal-Weight and raises the price target from $48 to $51.

Barclays Maintains Equal-Weight on RadNet, Raises Price Target to $51

The state of Maryland continues to expand access to crucial healthcare services. RadNet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services, made public statements to Maryland state committees in support of three bills on breast and lung screening. Maryland Governor Wes Moore recently signed those bills into state law, expanding residents&#39; access to affordable, preventive healthcare. 
&nbsp;
House Bill (HB) 1259, HB 0934, and HB 1293 address issues of affordability, quality, and education, respectively. These are the same issues that RadNet prioritizes in its commitment to deliver optimal results for patients. The new laws take effect in 2025.
HB 1259 expands breast and lung cancer screening coverage. Since January 1, 2024, Maryland-regulated insurers have been prohibited from imposing a copayment, coinsurance, or deductible on coverage for diagnostic mammograms, breast ultrasound, or breast Magnetic Resonance Imaging (MRI) for the detection and diagnosis of breast cancer. This has made imaging more accessible and affordable to patients in Maryland. The new bill now expands that legislation to include image-guided breast biopsy. Additionally, under HB 1259, Maryland-regulated insurers are now prohibited from imposing a copayment, coinsurance, or deductible on coverage for follow-up diagnostic imaging for lung cancer screening. Moreover, the coverage for lung imaging may not be subject to a prior authorization requirement, according to the new legislation.
HB 0934 addresses limited x-ray operator qualifications. Under this bill, individuals may now only perform certain x-ray examinations of the chest, spine, and extremities within physician offices under the supervision of a licensed physician or radiologic technologist. They must also meet specific training and education requirements, achieve a passing score on the ARRT examination or its equivalent, and complete 24 hours of approved continuing education credits every two-years. By tightening the licensing requirements for individuals performing these exams within physician offices, the new legislation ensures that imaging exams are performed only by qualified professionals.
HB 1293 requires the Maryland Department of Health (MDH) to develop and implement a three-year public education campaign on prostate, lung, and breast cancer prevention that targets communities disproportionately impacted by those cancers. Early detection has a strong impact on cancer survival rates, and RadNet welcomes this legislation as part of its overall commitment to health equity and access.

Government

Regulations

Maryland Expands Cancer Screening Access with New Laws Backed by RadNet

DAVID SWARTZ, Director at RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>), reported an insider sell on June 12, according to a new SEC filing. 
What Happened: SWARTZ's recent move involves selling 25,000 shares of RadNet. This information is documented in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000790526/000168316824004152//Archives/edgar/data/790526/000168316824004152/0001683168-24-004152-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total value is $1,518,841.
In the Thursday's morning session, RadNet's shares are currently trading at $61.75, experiencing a down of 0.0%.
<h3>Discovering RadNet: A Closer Look</h3>
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.
<h3>Breaking Down RadNet's Financial Performance</h3>
Revenue Growth: Over the 3 months period, RadNet showcased positive performance, achieving a revenue growth rate of 10.53% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 10.22%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): RadNet's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of -0.04.
</li>
</ul>
Debt Management: RadNet's debt-to-equity ratio surpasses industry norms, standing at 1.74. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 166.96, RadNet's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 2.52 is above industry norms, reflecting an elevated valuation for RadNet's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a below-average EV/EBITDA ratio of 17.95, RadNet presents an opportunity for value investors. This lower valuation may attract investors seeking undervalued opportunities.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Exploring Key Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000790526">Check Out The Full List Of RadNet's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RadNet Insider Trades Send A Signal

Jeffrey David Katz, EVP and Chief Legal Officer at RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>), disclosed an insider sell on June 11, according to a recent SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000790526/000168316824004127//Archives/edgar/data/790526/000168316824004127/0001683168-24-004127-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Katz sold 16,400 shares of RadNet. The total transaction amounted to $1,004,664. 
Monitoring the market, RadNet's shares down by 0.0% at $61.13 during Wednesday's morning.
<h3>All You Need to Know About RadNet</h3>
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.
<h3>RadNet: A Financial Overview</h3>
Revenue Growth: RadNet's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 10.53%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 10.22%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): RadNet's EPS reflects a decline, falling below the industry average with a current EPS of -0.04.
</li>
</ul>
Debt Management: RadNet's debt-to-equity ratio stands notably higher than the industry average, reaching 1.74. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Understanding Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 165.22 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 2.49, RadNet's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 17.8 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000790526">Check Out The Full List Of RadNet's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RadNet EVP and Chief Legal Officer Sold $1.00M In Company Stock

It was reported on June 11, that Nayoma Christine Gordon, Director at RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) executed a significant insider sell, according to an SEC filing.
What Happened: After conducting a thorough analysis, Gordon sold 4,500 shares of RadNet. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000790526/000168316824004125//Archives/edgar/data/790526/000168316824004125/0001683168-24-004125-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total transaction value is $275,445.
Tracking the Wednesday's morning session, RadNet shares are trading at $61.13, showing a down of 0.0%.
<h3>Get to Know RadNet Better</h3>
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.
<h3>Financial Milestones: RadNet's Journey</h3>
Revenue Growth: RadNet's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 10.53%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 10.22%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): RadNet's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of -0.04.
</li>
</ul>
Debt Management: RadNet's debt-to-equity ratio stands notably higher than the industry average, reaching 1.74. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: RadNet's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 165.22.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 2.49 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): RadNet's EV/EBITDA ratio at 17.8 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000790526">Check Out The Full List Of RadNet's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RadNet Director Trades $275K In Company Stock

In a report released today, David S Macdonald from Truist Financial assigned a Buy rating to Radnet (RDNT – Research Report). The company's shares ...

Radnet (RDNT) Receives a Buy from Truist Financial

RadNet, Inc. (RDNT) Q2 2024 Earnings Call Transcript

In a report released today, David S Macdonald from Truist Financial reiterated a Buy rating on Radnet (RDNT – Research Report). The company's share...

Truist Financial Sticks to Its Buy Rating for Radnet (RDNT)

RadNet: Growth In Operating Earnings Off Very Little Incremental Capital

RadNet's DeepHealth collaborates with HOPPR to advance healthcare AI

Radnet ( ($RDNT) ) has issued an update. RadNet, Inc. has announced the appointment of Kees Wesdorp as President and CEO of its Digital Health divi...

RadNet Names Kees Wesdorp as Digital Health Division CEO

Barclays analyst Andrew Mok CFA maintained a Buy rating on Radnet (RDNT – Research Report) today and set a price target of $79.00. The company's sh...

Barclays Sticks to Their Buy Rating for Radnet (RDNT)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bicycle Therapeutics (BCYC – Research Report) and Ra...

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC) and Radnet (RDNT)

In a report released today, David S Macdonald from Truist Financial reiterated a Buy rating on Radnet (RDNT – Research Report), with a price target...

Truist Financial Sticks to Their Buy Rating for Radnet (RDNT)

RadNet: Secular Tailwinds Underpinned By AI Monetization Prospects

BCYC

Press Releases

RadNet, Inc. to Present at the Jefferies 2024 Global Healthcare Conference on June 5, 2024

RadNet, Inc. to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

RadNet, Inc. to Present at the Sidoti & Company 2024 Small Cap Conference on Wednesday, June 12th

Politics

Maryland Passes Legislation Supported by RadNet to Expand Access to Breast and Lung Screening

RadNet, Inc. Announces Date of its Second Quarter 2024 Financial Results Conference Call

RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2024 Financial Guidance Ranges

RadNet, Inc. to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5th, 2024

RadNet's DeepHealth and HOPPR Forge Partnership to Advance AI in Healthcare

Management

RadNet, Inc. Announces the Appointment of Kees Wesdorp as President and Chief Executive Officer of RadNet's Digital Health Division

RadNet, Inc. to Present at the Sidoti & Company Small Cap 2024 Virtual Conference on Wednesday, September 18th

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

RadNet

Intérêt court

RadNet (NASDAQ:RDNT) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL